Shares of several global generic drug manufacturers experienced a decline subsequent to President Donald Trump's declaration that the United States will implement tariffs on these medications. The tariffs are slated to take effect in August 2028.
The announcement prompted a downward movement in the stock prices of various European and Asian companies specializing in the production of generic pharmaceuticals. While specific companies were not detailed, the broad impact suggests a significant concern among investors regarding the future profitability and market access for these manufacturers in the U.S.